[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604134":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":21,"locations":31,"responsibleParty":53,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Severe diabetic microangiopathy",null,"Severe micro-angiopathy defined as proliferative retinopathy, macroalbuminuria, and kidney failure with at least CKD-class 3B and severe neuropathy with or without foot ulcers. Aged 18-60 years old.",{"label":13,"type":10,"description":14,"interventionNames":10},"Moderate diabetic microangiopathy","Moderate non-proliferative retinopathy or proliferative retinopathy, macroalbuminuria or kidney failure defined as estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2 body surface, and manifest neuropathy. Aged 18-45 years old.",{"label":16,"type":10,"description":17,"interventionNames":10},"Mild diabetic microangiopathy","Mild-moderate non-proliferative retinopathy and\u002For microalbuminuria and\u002For early signs of neuropathy. Aged 18-45 years old.",{"label":19,"type":10,"description":20,"interventionNames":10},"No diabetic microangiopathy","No microangiopathic complications, except for simplex or background retinopathy, which is an early and reversible state. Aged 18-45 years old.",[22,27],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Sara Tehrani, Medical Doctor","CONTACT","+46 08 123 550 00","sara.tehrani@ki.se",{"name":28,"role":24,"phone":29,"phoneExt":10,"email":30},"Jacob Widaeus, Medical Doctor","+46 08 123 596 01","jacob.widaeus@ki.se",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Danderyd University Hospital","RECRUITING","Danderyd","Stockholm County","182 88","Sweden","SE",{"type":41,"coordinates":42},"Point",[43,44],18.02376,59.40398,{"lat":44,"lon":43},[47,49,51],{"name":23,"role":24,"phone":48,"phoneExt":10,"email":26},"+460812355000",{"name":28,"role":24,"phone":50,"phoneExt":10,"email":30},"+460812359601",{"name":23,"role":52,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sara Tehrani","Principal investigator, Medical doctor, Specialist in internal medicine",[57],{"name":58,"class":59},"Neko Health AB","UNKNOWN","100604134","microangiopathy-in-diabetes-100604134",false,"NCT07145567","Microangiopathy in Diabetes","Microangiopathy IN Diabetes","MIND","Inclusion Criteria:\n\n* Diabetes mellitus type 1.\n* Cohort specific inclusion criteria apply, please review 'groups' section.\n\nExclusion Criteria:\n\n* Patients unable to understand patient information due to cognitive impairment.\n* Patients unable to understand patient information due to language barriers.\n* Ongoing acute infection disease or inflammatory condition.\n* Pregnant or breast-feeding women.\n* Patients with damaged and\u002For scarred tissue in the areas of interest for the investigational or comparator devices.",true,"ALL","18 Years","60 Years",{"count":73,"type":74},400,"ESTIMATED","OBSERVATIONAL","This clinical trial aims to evaluate the use of a contactless and non-invasive technique to measure the properties of the skin's microcirculation and its regulatory functions in both healthy individuals and patients with microvascular disease associated with type 1 diabetes. It is hoped that the study results will lead to the development of a useful method for detecting diabetic complications at an early stage, thereby enabling treatment and preventive measures before the onset of severe microangiopathy.",[78,79],"Microangiopathy","Microvascular Complications",[81,82,83,84,85,86],"Laser speckle contrast imaging","Spatial frequency domain imaging","Laser doppler flowmetry","Iontophoresis","Local thermal hyperemia","Post occlusive reactive hyperemia","2025-08-21",{"date":89,"type":90},"2025-08-28","ACTUAL",{"date":92,"type":90},"2024-03-01",{"date":94,"type":74},"2027-12",{"name":5,"class":6},1]